Myasthenie.com

J Formos Med Assoc. 2026 Mar 27:S0929-6646(26)00255-X. doi: 10.1016/j.jfma.2026.03.085. Online ahead of print.

ABSTRACT

BACKGROUND AND PURPOSE: Thymoma-associated myasthenia gravis (TAMG) patients with anti-titin antibodies exhibit uncertain clinical and immunological relevance.

METHODS: We analyzed 91 TAMG patients (40 Titin + group, 51 Titin- group) treated between 2019 and 2025. Clinical features, severity scores, and peripheral immune markers were compared, and finally tested the correlation between the latter and severity.

RESULTS: Titin + group had higher rates of MGFA ≥ III (55.0% vs. 25.5%, p = 0.004) and elevated QMG bulbar scores [3.00 (0.75-3.00) vs. 0.00 (0.00-0.00), p = 0.002]. They also showed increased platelets (249.4 ± 62.0 vs. 224.2 ± 48.0 × 109/L, p = 0.033), monocytes (0.59 ± 0.27 vs. 0.46 ± 0.23 × 109/L, p = 0.018), and IL-1β [4.20 (1.85-12.06) vs. 1.13 (0.46-3.13) pg/mL, p = 0.009]. IL-6 correlated with MGFA class (r = 0.67, p = 0.004) and QMG respiratory scores (r = 0.70, p = 0.026); NLR with QMG (r = 0.60, p = 0.018) and MG-ADL (r = 0.53, p = 0.044); TNF-α (r = 0.86, p = 0.014) and IL-8 (r = 0.79, p = 0.036) with MG-QoL15; PLR with QMG gross motor (r = 0.53, p = 0.041) and bulbar scores (r = 0.58, p = 0.025); SII and IL-2 with QMG bulbar (r = 0.53, p = 0.046) and respiratory scores (r = 0.78, p = 0.040), respectively.

CONCLUSION: Anti-titin antibodies positive TAMG is associated with more severe disease-especially bulbar involvement. NLR, PLR, IL-2, IL-6, IL-8, and TNF-α are candidate biomarkers of severity.

PMID:41904038 | DOI:10.1016/j.jfma.2026.03.085


Source: https://pubmed.ncbi.nlm.nih.gov/4190403 ... t6+133c1fe